Fort St. John racers compete in Whitecourt Carlan Cup

first_imgWHITECOURT, A.B. — Three Fort St. John jet boat racers were in Whitecourt last weekend, competing in the 2017 Whitecourt Carlan Cup Riverboat Races.Gord Humprey piloted Unnatural Disaster on the race’s four legs in a total time of 1:23:44. Humphrey finished second in the Tri Jet Services division, behind Chad Burns. His time was also the second-fastest overall.Two other jet boat drivers from Fort St. John were also competing in the Carlan Cup. Racing in the Kehoe Marine division, Trapper Wolsey finished 3rd in that division at the wheel of his boat, Leroy. Wolsey recorded a time of 1:50:47, while Clayton Wolsey finished in 6th out of seven racers. Clayton piloted Dirty Harry to a time of 1:54:45.- Advertisement –last_img

All smiles as Eli Lilly exceeds projections

first_img The company said it expects to submit five new products to government regulators for review in the next four years as it seeks new indications for existing products. It plans to submit an application for Arxxant, a drug to prevent blindness caused by diabetes, to regulators by the end of February. Some analysts were expecting a submission later this year but don’t believe the delay is significant. Another drug that has piqued analysts’ interest is blood thinner Prasugrel, which the company expects to submit in 2007. Analysts agree Prasugrel has blockbuster potential. Lilly also said it plans to reduce the average development cost for new drugs by one-third, to $800 million from $1.2 billion by the end of the decade. Lilly shares rose $1.20, or 2.3 percent, to close at $53.41 Friday on the New York Stock Exchange. NEW YORK – Drug maker Eli Lilly and Co. on Friday said it would post earnings per share at the high end of its forecast for this year, and its estimates for next year topped analysts’ projections. Its share price rose more than 2 percent in late trading. The company said, excluding items, it expects to come in at the top of its earnings outlook of $2.80 to $2.86 per share for 2005. Including a charge to settle a product-liability dispute in the second quarter for its anti-psychotic medication Zyprexa, the company expects full-year earnings per share at the high end of a $1.90 to $1.96 range. For 2006, the company forecast earnings per share of $3.10 to $3.20 excluding items. Analysts surveyed by Thomson Financial predicted earnings of $3.08 in 2006. 160Want local news?Sign up for the Localist and stay informed Something went wrong. Please try again.subscribeCongratulations! You’re all set!last_img read more